Insecticidal mosquito vector control products are vital components of malaria control programmes. Test facilities are key in assessing the effectiveness of vector control products against local mosquito populations, in environments where they will be used. Data from these test facilities must be of a high quality to be accepted by regulatory authorities, including the WHO Prequalification Team for vector control products. In 2013–4, seven insecticide testing facilities across sub-Saharan Africa, with technical and financial support from Innovative Vector Control Consortium (IVCC), began development and implementation of quality management system compliant with the principles of Good Laboratory Practice (GLP) to improve data quality and reliability.

Take a deep dive into the ground-breaking New Nets Project! Funded by @Unitaid and the @Global Fund, and spearheaded by the Innovative Vector Control Consortium (IVCC), this initiative piloted the use of dual-insecticide mosquito nets in malaria-endemic countries from 2019 to 2022.

In this video, we explore the incredible impact of introducing 56 million state-of-the-art mosquito nets across 17 countries in sub-Saharan Africa. Discover how these innovative nets have averted an estimated 13 million malaria cases and saved 24,600 lives, especially in areas grappling with insecticide-resistant mosquitoes.

The Vector Expedited Review Voucher (VERV), modelled on the already established US Priority Review Voucher (PRV) for drug development, is a proposed no cost new incentive to encourage R&D focussed agriculture companies to innovate in public health where there are significant economic barriers to product innovation. The VERV would encourage companies to invest in novel insecticide development for public health, such as malaria, by rewarding the registrant of a new public health insecticide with a voucher to receive an expedited review of a second, more profitable product outside public health. Getting to market faster is valuable and gives an innovator registrant an opportunity to generate a financial return to mitigate the development cost losses on a public health use insecticide.

This study assesses development of new medicines and technologies for 35 poverty-related and neglected diseases, including HIV/AIDS, malaria and tuberculosis. The findings and recommendations will help shape future investments and activities in this field for the UK government and other major government donors and philanthropies.